Gossamer Bio Inc (GOSS)
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker GOSS. The company is focused on developing and commercializing seralutinib for pulmonary hypertension, including pulmonary arterial hypertension, in the United States. Its pipeline also includes GB002, an inhaled small-molecule inhibitor targeting PDGFR, colony-stimulating factor 1 receptor, and c-KIT, which is in Phase 3 clinical testing for PAH. Gossamer Bio has license agreements with Pulmokine, Inc. covering GB002 and related backup compounds. Founded in 2015 and formerly known as FSG, Bio, Inc., the company adopted its current name in 2017 and is headquartered in San Diego, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-GOSS
|
$0.20
|
31.1% Upside
|
Undervalued
|
$3.86 2,470.7% Upside
|
—
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 11, 2026
|
-0.4x
|
-0.5x
|
1.3x
|
68.927 M
|
177 M
|
74.6%
|
58.8%
|
-19.3
|
—
|
94.4%
|
